Gyre Therapeutics, Inc.
DE ˙ DB ˙ US4037831033
4,92 € ↓ -0,08 (-1,60%)
2026-06-02
AKTIENPREIS
SecurityDE:L9S / Gyre Therapeutics, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership1,201,589 shares
Latest Disclosed Value $ 8,483,219
Vanguard Group Inc reports 4.44% increase in ownership of L9S / Gyre Therapeutics, Inc.

On January 29, 2026 - Vanguard Group Inc filed a 13F-HR form disclosing ownership of 1,201,589 shares of Gyre Therapeutics, Inc. (DE:L9S) valued at $7,269,613 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 7, 2025 disclosing 1,150,559 shares of Gyre Therapeutics, Inc.. This represents a change in shares of 4.44% during the quarter. The current value of the position is $5,911,818 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F GYRE THERAPEUTICS COM 403783103 1,201,589 51,030 4.44 8,483 -1.17 0.0001
2025-11-07 2025-09-30 13F GYRE THERAPEUTICS COM 403783103 1,150,559 850 0.07 8,583 1.57 0.0001
2025-08-11 2025-06-30 13F GYRE THERAPEUTICS COM 403783103 1,149,709 53,221 4.85 8,450 -0.17 0.0001
2025-05-09 2025-03-31 13F GYRE THERAPEUTICS COM 403783103 1,096,488 774,024 240.03 8,465 116.97 0.0002
2025-02-11 2024-12-31 13F GYRE THERAPEUTICS COM 403783103 322,464 -17,707 -5.21 3,902 -8.53 0.0001
2024-11-13 2024-09-30 13F GYRE THERAPEUTICS COM 403783103 340,171 108,530 46.85 4,266 54.36 0.0001
2024-08-13 2024-06-30 13F GYRE THERAPEUTICS COM 403783103 231,641 36,543 18.73 2,763 -18.97 0.0001
2024-05-10 2024-03-31 13F GYRE THERAPEUTICS COM 403783103 195,098 -2,999 -1.51 3,410 -32.99 0.0001
2024-03-11 2023-12-31 13F/A-1 GYRE THERAPEUTICS COM 403783103 198,097 198,097 5,089 0.0001
2024-02-14 2023-12-31 13F GYRE THERAPEUTICS COM 403783103 198,097 198,097 5,089 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.